-
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
This is a single arm, multi-site, open-label trial of pembrolizumab (MK-3475) in subjects with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin ...Phase
Interventional
-
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
The Pediatric MATCH (Molecular Analysis for Therapy Choice) study, (referred to as Pediatric MATCH in the remainder of this document), will match targeted agents with ...Phase
Non-Interventional
-
NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
High risk Neuroblastoma (HR NB) remains a challenge in pediatric oncology, accounting for 15% of all pediatric cancer deaths. While most patients are able to ...Phase
Interventional
-
PNH Registry
Alexion Pharmaceuticals, Inc. has been the Sponsor of a global PNH Registry since August 2004 and enrolling patients with PNH worldwide. The primary aim of ...Phase
Non-Interventional
-
A single arm open-label multicenter phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma
This single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients ...Phase
Interventional
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Study 849-001 is a multi-center, Phase 1/2, multiple expansion cohort trial evaluating the safety, PK, metabolites, PD and clinical activity/efficacy of MRTX849 in ...Phase
Interventional
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The optimal treatment for children and adolescents with Ph+ ALL has not yet been determined. There is now a general consensus among the North American ...Phase
Interventional
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Nivolumab will be investigated at the Food and Drug Administration (FDA)-approved dose of 480 mg intravenous (IV) every 4 weeks until unacceptable toxicity, disease ...Phase
Interventional
-
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Low-grade gliomas (LGG) are the most common central nervous system (CNS) tumors in the pediatric population. Although the etiology of most childhood LGG is unknown ...Phase
Interventional
-
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical ...Phase N/A Interventional
